Eli Lilly and Company (LLY) vs Vanguard S&P 500 ETF (VOO)
See how Eli Lilly and Company and Vanguard S&P 500 ETF differ across market data and performance, so you can decide which asset best fits your strategy.
$1,179.11
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
Vanguard S&P 500 ETF is an exchange-traded fund that gives investors diversified exposure to large-cap U.S. companies in the S&P 500 Index. It is designed to track or represent a basket of publicly traded securities rather than a single company, making it useful for portfolio allocation, regional exposure, and thematic positioning. Its performance depends on the underlying holdings, sector and country weights, currency movements where relevant, fund expenses, and broader equity-market conditions.